ArticleProceedings of the National Academy of Sciences of the United States of America2020
Optimization of a
Article in Proceedings of the National Academy of Sciences of the United States of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 34 citations in OpenAlex.
- Protective near-germline antibodies to malaria elicited by RTS,S/AS01bioRxiv : the preprint server for biology · 2026Article
- Comparative assessment of tissue cross-reactivity and pharmacokinetic half-life of malaria monoclonal antibodies.Frontiers in immunology · 2026Article
- A Plasmodium-derived nanoparticle vaccine elicits sterile protection against malaria in mice.Nature microbiology · 2026Article
- Comparison of major, minor and junctional circumsporozoite protein epitopes for malaria vaccine design.NPJ vaccines · 2025Article
- A combined designed CSP and Pfs48/45 infection and transmission blocking vaccine for malaria.NPJ vaccines · 2025Article
- Elicitation of liver-stage immunity by nanoparticle immunogens displaying P. falciparum CSP-derived antigens.NPJ vaccines · 2025Article
- Recombinant Full-length Plasmodium falciparum Circumsporozoite Protein-Based Vaccine Adjuvanted With Glucopyranosyl Lipid A-Liposome Quillaja saponaria 21: Results of Phase 1 Testing With Malaria Challenge.The Journal of infectious diseases · 2024Article
- TargetingVaccines · 2024Review
- Article
- A candidate antibody drug for prevention of malaria.Nature medicine · 2024Article
- Pseudovirus Nanoparticles DisplayingVaccines · 2023Article
- Protective antibody threshold of RTS,S/AS01 malaria vaccine correlates antigen and adjuvant dose in mouse model.NPJ vaccines · 2023Article
- Affinity-matured homotypic interactions induce spectrum of PfCSP structures that influence protection from malaria infection.Nature communications · 2023Article
- Glycosylated nanoparticle-based PfCSP vaccine confers long-lasting antibody responses and sterile protection in mouse malaria model.NPJ vaccines · 2023Article
- Humoral Immune Responses toInfection and drug resistance · 2023Review
- Antigen- and scaffold-specific antibody responses to protein nanoparticle immunogens.Cell reports. Medicine · 2022Article
- How to induce protective humoral immunity against Plasmodium falciparum circumsporozoite protein.The Journal of experimental medicine · 2022Review
- Restricted valency (NPNA)NPJ vaccines · 2022Article
- SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity.Cell reports · 2021Article
- Vaccine delivery systems toward lymph nodes.Advanced drug delivery reviews · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.